

B, T A T, T, I A A, I, ,

De Novo Lipogenesis Inhibitors: As the other innovative agents for therapy of Metabolic Diseases (Obesity, NAFLD/NASH, CVD) - A narrative Review

Kulvinder Kochar Kaur

Scientific Director of Dr Kulvinder Kaur Centre for Human Reproduction

For survival fatty acids is necessary, working as substrates for bioenergy generation, structural constituents along with signaling molecules. With their key part, evolutionary modes by cells for fatty acids formation from alternative carbon resources via an event labeled as de novo" lipogenesis (DNL). In spite of the knowledge of significance regarding it's up regulation abnormalities being correlated with numerous types of pathological conditions. Attempt at hampering core DNL enzymes inclusive of citrate/iso citrate carrier(CIC),ATP citrate lyase (ACLY), acetyl-coA carboxylase(ACC) along with fatty acid synthase(FAS) apparently should turn out to be a good therapeutic approach. Although numerous hurdles anticipated regarding effectiveness, selectiveness besides safety variable newer